JP2008523094A5 - - Google Patents

Download PDF

Info

Publication number
JP2008523094A5
JP2008523094A5 JP2007545671A JP2007545671A JP2008523094A5 JP 2008523094 A5 JP2008523094 A5 JP 2008523094A5 JP 2007545671 A JP2007545671 A JP 2007545671A JP 2007545671 A JP2007545671 A JP 2007545671A JP 2008523094 A5 JP2008523094 A5 JP 2008523094A5
Authority
JP
Japan
Prior art keywords
seq
sequence
pharmaceutical composition
oligonucleotide
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007545671A
Other languages
English (en)
Japanese (ja)
Other versions
JP4981681B2 (ja
JP2008523094A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/044662 external-priority patent/WO2006063252A2/en
Publication of JP2008523094A publication Critical patent/JP2008523094A/ja
Publication of JP2008523094A5 publication Critical patent/JP2008523094A5/ja
Application granted granted Critical
Publication of JP4981681B2 publication Critical patent/JP4981681B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007545671A 2004-12-09 2005-12-09 哺乳類における免疫応答誘導組成物および方法、ならびに短鎖干渉ｒｎａなどのオリゴヌクレオチド剤に対する免疫応答の回避方法 Expired - Lifetime JP4981681B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63484904P 2004-12-09 2004-12-09
US60/634,849 2004-12-09
PCT/US2005/044662 WO2006063252A2 (en) 2004-12-09 2005-12-09 Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering rnas

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011221109A Division JP2012031191A (ja) 2004-12-09 2011-10-05 哺乳類における免疫応答誘導組成物および方法、ならびに短鎖干渉ｒｎａなどのオリゴヌクレオチド剤に対する免疫応答の回避方法

Publications (3)

Publication Number Publication Date
JP2008523094A JP2008523094A (ja) 2008-07-03
JP2008523094A5 true JP2008523094A5 (enExample) 2011-11-24
JP4981681B2 JP4981681B2 (ja) 2012-07-25

Family

ID=36578622

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007545671A Expired - Lifetime JP4981681B2 (ja) 2004-12-09 2005-12-09 哺乳類における免疫応答誘導組成物および方法、ならびに短鎖干渉ｒｎａなどのオリゴヌクレオチド剤に対する免疫応答の回避方法
JP2011221109A Pending JP2012031191A (ja) 2004-12-09 2011-10-05 哺乳類における免疫応答誘導組成物および方法、ならびに短鎖干渉ｒｎａなどのオリゴヌクレオチド剤に対する免疫応答の回避方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011221109A Pending JP2012031191A (ja) 2004-12-09 2011-10-05 哺乳類における免疫応答誘導組成物および方法、ならびに短鎖干渉ｒｎａなどのオリゴヌクレオチド剤に対する免疫応答の回避方法

Country Status (6)

Country Link
US (2) US8003619B2 (enExample)
EP (1) EP1819365B1 (enExample)
JP (2) JP4981681B2 (enExample)
AU (1) AU2005313883B2 (enExample)
CA (1) CA2589406A1 (enExample)
WO (1) WO2006063252A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977245B2 (en) * 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
AU2003230806B2 (en) 2002-04-04 2009-05-07 Zoetis Belgium S.A. Immunostimulatory G,U-containing oligoribonucleotides
CN102604957B (zh) * 2003-06-11 2015-10-07 艾德拉药物股份有限公司 稳定的免疫调节寡核苷酸
US20060134189A1 (en) * 2004-11-17 2006-06-22 Protiva Biotherapeutics, Inc siRNA silencing of apolipoprotein B
US20070054873A1 (en) * 2005-08-26 2007-03-08 Protiva Biotherapeutics, Inc. Glucocorticoid modulation of nucleic acid-mediated immune stimulation
CN101346393B (zh) 2005-11-02 2015-07-22 普洛体维生物治疗公司 修饰的siRNA分子及其应用
US7662949B2 (en) 2005-11-25 2010-02-16 Coley Pharmaceutical Gmbh Immunostimulatory oligoribonucleotides
US7915399B2 (en) * 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
EP4082551A1 (en) 2006-08-08 2022-11-02 Rheinische Friedrich-Wilhelms-Universität Bonn Structure and use of 5' phosphate oligonucleotides
CA2660204A1 (en) * 2006-08-16 2008-02-21 Protiva Biotherapeutics, Inc. Nucleic acid modulation of toll-like receptor-mediated immune stimulation
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
EP2297323A1 (en) 2008-05-21 2011-03-23 Hartmann, Gunther 5' triphosphate oligonucleotide with blunt end and uses thereof
US9394333B2 (en) 2008-12-02 2016-07-19 Wave Life Sciences Japan Method for the synthesis of phosphorus atom modified nucleic acids
WO2010141511A2 (en) 2009-06-01 2010-12-09 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent rna interference, compositions and methods of use thereof
WO2011000108A1 (en) * 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein b
MX342945B (es) 2009-07-06 2016-10-18 Ontorii Inc * Profármacos de ácido nucleico novedosos y métodos de uso de los mismos.
EA025341B1 (ru) 2010-09-22 2016-12-30 Алиос Биофарма, Инк. Замещенные аналоги нуклеотидов
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
WO2012079115A1 (en) * 2010-12-14 2012-06-21 Commonwealth Scientific And Industrial Research Organisation Immunostimulatory oligonucleotides
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
US8980865B2 (en) 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
HK1203356A1 (en) 2012-03-22 2015-10-30 艾丽奥斯生物制药有限公司 Pharmaceutical combinations comprising a thionucleotide analog
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
KR20240148947A (ko) 2012-07-13 2024-10-11 웨이브 라이프 사이언시스 리미티드 키랄 제어
SG11201500243WA (en) * 2012-07-13 2015-04-29 Shin Nippon Biomedical Lab Ltd Chiral nucleic acid adjuvant
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
US20150366890A1 (en) 2013-02-25 2015-12-24 Trustees Of Boston University Compositions and methods for treating fungal infections
EP3095460A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
ES2917473T3 (es) 2014-01-16 2022-07-08 Wave Life Sciences Ltd Diseño quiral
EP3340967B1 (en) 2015-08-24 2024-05-22 Halo-Bio Rnai Therapeutics, Inc. Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
FI4104687T3 (fi) 2015-09-21 2024-03-01 Trilink Biotechnologies Llc Koostumuksia ja menetelmiä 5-huputettujen RNA:iden syntetisoimiseksi
JP6583864B2 (ja) * 2015-09-30 2019-10-09 塩野義製薬株式会社 免疫賦活活性を有する核酸誘導体
US10940201B2 (en) 2015-09-30 2021-03-09 Shionogi & Co., Ltd. Nucleic acid derivative having immunostimulatory activity
WO2018067302A2 (en) * 2016-09-19 2018-04-12 North Western University Therapeutic effects of cellular delivery of small molecules and macromolecules with liposomal spherical nucleic acids
CN112105733B (zh) 2018-04-19 2024-10-29 查美特制药公司 合成rig-i样受体激动剂
EP3909612A1 (en) 2020-05-12 2021-11-17 Life Science Inkubator Betriebs GmbH & Co. KG Composition of nanoparticles
US20230183703A1 (en) * 2020-05-15 2023-06-15 Howard University Compositions and methods for treating and detecting coronavirus infection
JP2023526090A (ja) 2020-05-19 2023-06-20 ハドソン インスティチュート オブ メディカル リサーチ オリゴヌクレオチド
EP4323525A2 (en) * 2021-04-16 2024-02-21 Genentech, Inc. Optimized tlr7 ligands and uses thereof
WO2024145478A1 (en) * 2022-12-30 2024-07-04 Salk Institute For Biological Studies Transcription factors controlling t cell differentiation and disruption for tumor and virus control

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US5652355A (en) 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
US6346614B1 (en) 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
TW244371B (enExample) 1992-07-23 1995-04-01 Tri Clover Inc
WO1995028493A1 (en) 1994-04-13 1995-10-26 The Rockefeller University Aav-mediated delivery of dna to cells of the nervous system
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US6235310B1 (en) 1997-04-04 2001-05-22 Valentis, Inc. Methods of delivery using cationic lipids and helper lipids
JP2002500201A (ja) 1998-01-05 2002-01-08 ユニバーシティ オブ ワシントン 膜破壊剤を使用する増強された輸送
WO2000003683A2 (en) 1998-07-20 2000-01-27 Inex Pharmaceuticals Corporation Liposomal encapsulated nucleic acid-complexes
AU783687B2 (en) * 2000-01-26 2005-11-24 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
WO2003070918A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
US6413881B1 (en) * 2000-03-09 2002-07-02 Lsi Logic Corporation Process for forming thin gate oxide with enhanced reliability by nitridation of upper surface of gate of oxide to form barrier of nitrogen atoms in upper surface region of gate oxide, and resulting product
WO2001093902A2 (en) * 2000-06-07 2001-12-13 Biosynexus Incorporated Immunostimulatory rna/dna hybrid molecules
US20030077829A1 (en) 2001-04-30 2003-04-24 Protiva Biotherapeutics Inc.. Lipid-based formulations
WO2003070910A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20050159376A1 (en) * 2002-02-20 2005-07-21 Slrna Therapeutics, Inc. RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
US20030130186A1 (en) 2001-07-20 2003-07-10 Chandra Vargeese Conjugates and compositions for cellular delivery
US6586524B2 (en) 2001-07-19 2003-07-01 Expression Genetics, Inc. Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier
AU2002338926B2 (en) * 2001-11-05 2007-05-24 Janssen Pharmaceutica N.V. Method for the in vitro synthesis of short double stranded RNAs
AU2003207708A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US6683366B1 (en) 2002-06-04 2004-01-27 Newport Fab, Llc Bipolar transistor and related structure
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
US20050106731A1 (en) 2002-08-05 2005-05-19 Davidson Beverly L. siRNA-mediated gene silencing with viral vectors
AU2003301348A1 (en) * 2002-10-18 2004-05-04 Wyeth Compositions and methods for diagnosing and treating autoimmune disease
US8090542B2 (en) * 2002-11-14 2012-01-03 Dharmacon Inc. Functional and hyperfunctional siRNA
US20040180848A1 (en) 2003-03-10 2004-09-16 Fesik Stephen W. Method of killing cancer cells
ES2216707B1 (es) 2003-04-08 2005-12-16 Josep Maria Aran Perramon Secuencia oligoribonucleotidica homologa a una region del cdna que codifica para el receptor cd40 humano y oligoribonucleotidos duplex, vectores, composiciones farmaceuticas y usos correspondientes.
CA2558417A1 (en) 2004-03-05 2005-09-22 Holland Lp Multipurpose lading tie anchor system for securing cargo

Similar Documents

Publication Publication Date Title
JP2008523094A5 (enExample)
Kang et al. Small interfering RNA (siRNA)-based therapeutic applications against viruses: principles, potential, and challenges
JP7108011B2 (ja) ５’リン酸オリゴヌクレオチドの構造および使用
KR101343489B1 (ko) 안정화된 면역 조절성 ｒｎａ（ｓｉｍｒａ）화합물
JP5805088B2 (ja) 遺伝子発現を阻害する組成物およびその使用
KR101221589B1 (ko) Ｔｌｒ７ 및 ｔｌｒ８에 대한 안정화된 면역 조절성 ｒｎａ〔ｓｉｍｒａ〕 화합물
JP2024150603A (ja) Ｂ型肝炎ウイルス感染のためのＲＮＡｉ薬
CN103333890B (zh) 治疗乙型病毒性肝炎的rna干扰制剂
US8288358B2 (en) Therapeutic targets and molecules
JP2024518546A (ja) 修飾されたｍＲＮＡ、修飾された非コードＲＮＡ、およびその使用
CN111511914B (zh) 减少PAPD5和PAPD7 mRNA的核酸分子用于治疗乙型肝炎感染
AU2010213795A1 (en) Synthetic RNA-based agonists of TLR7
JPWO2021028439A5 (enExample)
CN113507920A (zh) 用于乙型肝炎病毒感染的RNAi剂
AU2014205544B2 (en) Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
WO2016149323A1 (en) Immunomodulatory spherical nucleic acids
JP2023506546A (ja) Ｂ型肝炎ウイルス感染症を処置するためのｓｅｐｔ９阻害剤の使用
TW202020152A (zh) 調節rtel1表現之寡核苷酸
KR20210144601A (ko) 이중가닥 올리고뉴클레오티드 및 이를 포함하는 코로나바이러스감염증-19〔covid-19〕치료용 조성물
JP2023506547A (ja) Ｂ型肝炎ウイルス感染を処置するためのｃｏｐｓ３阻害剤の使用
Richardt‐Pargmann et al. Stimulation of the immune system by therapeutic antisense oligodeoxynucleotides and small interfering RNAs via nucleic acid receptors: How to avoid immune activation
CN111154755A (zh) 一种双链寡核苷酸dna及其应用
Mehrotra et al. Therapeutic potential of miRNAs in parasitic infectious diseases
JP2026502546A (ja) インフルエンザＡ型ウイルス遺伝子発現を阻害するためのＲＮＡｉ剤、その組成物、及び使用方法
TW202444904A (zh) 用於抑制粒線體醯胺肟還原組分1(MARC1)之表現之RNAi藥劑、其醫藥組合物及使用方法